FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3044281874> ?p ?o ?g. }

• W3044281874 endingPage "9406" @default.
• W3044281874 startingPage "9395" @default.
• W3044281874 abstract "Tumor-associated hypoxia influences the radiation response of head-and-neck cancer (HNSCC) patients, and a lack of early hypoxia resolution during treatment considerably deteriorates outcomes. As the detrimental effects of hypoxia are partly related to the induction of an immunosuppressive microenvironment, we investigated the interaction between tumor hypoxia dynamics and the PD-1/PD-L1 axis in HNSCC patients undergoing chemoradiation and its relevance for patient outcomes in a prospective trial. Methods: 49 patients treated with definitive chemoradiation for locally advanced HNSCC were enrolled in this trial and received longitudinal hypoxia PET imaging using fluorine-18 misonidazole ([18F]FMISO) at weeks 0, 2 and 5 during treatment. Pre-therapeutic tumor biopsies were immunohistochemically analyzed regarding the PD-1/PD-L1 expression both on immune cells and on tumor cells, and potential correlations between the PD-1/PD-L1 axis and tumor hypoxia dynamics during chemoradiation were assessed using Spearman's rank correlations. Hypoxia dynamics during treatment were quantified by subtracting the standardized uptake value (SUV) index at baseline from the SUV values at weeks 2 or 5, whereby SUV index was defined as ratio of maximum tumor [18F]FMISO SUV to mean SUV in the contralateral sternocleidomastoid muscle (i.e. tumor-to-muscle ratio). The impact of the PD-1/PD-L1 expression alone and in combination with persistent tumor hypoxia on locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) was examined using log-rank tests and Cox proportional hazards models. Results: Neither PD-L1 nor PD-1 expression levels on tumor-infiltrating immune cells influenced LRC (HR = 0.734; p = 0.480 for PD-L1, HR = 0.991; p = 0.989 for PD-1), PFS (HR = 0.813; p = 0.597 for PD-L1, HR = 0.796; p = 0.713 for PD-1) or OS (HR = 0.698; p = 0.405 for PD-L1, HR = 0.315; p = 0.265 for PD-1). However, patients with no hypoxia resolution between weeks 0 and 2 and PD-L1 expression on tumor cells, quantified by a tumor proportional score (TPS) of at least 1%, showed significantly worse LRC (HR = 3.374, p = 0.022) and a trend towards reduced PFS (HR = 2.752, p = 0.052). In the multivariate Cox regression analysis, the combination of absent tumor hypoxia resolution and high tumoral PD-L1 expression remained a significant prognosticator for impaired LRC (HR = 3.374, p = 0.022). On the other side, tumoral PD-L1 expression did not compromise the outcomes of patients whose tumor-associated hypoxia declined between week 0 and 2 during chemoradiation (LRC: HR = 1.186, p = 0.772, PFS: HR = 0.846, p = 0.766). Conclusion: In this exploratory analysis, we showed for the first time that patients with both persistent tumor-associated hypoxia during treatment and PD-L1 expression on tumor cells exhibited a worse outcome, while the tumor cells' PD-L1 expression did not influence the outcomes of patients with early tumor hypoxia resolution. While the results have to be validated in an independent cohort, these findings form a foundation to investigate the combination of hypoxic modification and immune checkpoint inhibitors for the unfavorable subgroup, moving forward towards personalized radiation oncology treatment." @default.
• W3044281874 created "2020-07-29" @default.
• W3044281874 creator A5001611482 @default.
• W3044281874 creator A5010549062 @default.
• W3044281874 creator A5045042817 @default.
• W3044281874 creator A5045238287 @default.
• W3044281874 creator A5047091127 @default.
• W3044281874 creator A5059169023 @default.
• W3044281874 creator A5062987908 @default.
• W3044281874 creator A5080877411 @default.
• W3044281874 creator A5081477925 @default.
• W3044281874 creator A5089050618 @default.
• W3044281874 creator A5090066209 @default.
• W3044281874 date "2020-01-01" @default.
• W3044281874 modified "2023-10-14" @default.
• W3044281874 title "Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation" @default.
• W3044281874 cites W1910012553 @default.
• W3044281874 cites W1977020389 @default.
• W3044281874 cites W1978370833 @default.
• W3044281874 cites W1983270572 @default.
• W3044281874 cites W1991880013 @default.
• W3044281874 cites W2006089496 @default.
• W3044281874 cites W2028107411 @default.
• W3044281874 cites W2035517438 @default.
• W3044281874 cites W2057290654 @default.
• W3044281874 cites W2066210329 @default.
• W3044281874 cites W2069240289 @default.
• W3044281874 cites W2083100780 @default.
• W3044281874 cites W2084341371 @default.
• W3044281874 cites W2084486398 @default.
• W3044281874 cites W2093155570 @default.
• W3044281874 cites W2099268944 @default.
• W3044281874 cites W2105332214 @default.
• W3044281874 cites W2115851943 @default.
• W3044281874 cites W2118373200 @default.
• W3044281874 cites W2124363070 @default.
• W3044281874 cites W2138378181 @default.
• W3044281874 cites W2142616933 @default.
• W3044281874 cites W2149360266 @default.
• W3044281874 cites W2151170616 @default.
• W3044281874 cites W2154981748 @default.
• W3044281874 cites W2157607856 @default.
• W3044281874 cites W2159964832 @default.
• W3044281874 cites W2163763232 @default.
• W3044281874 cites W2166760412 @default.
• W3044281874 cites W2176647747 @default.
• W3044281874 cites W2210073947 @default.
• W3044281874 cites W2289333985 @default.
• W3044281874 cites W2299264726 @default.
• W3044281874 cites W2337795947 @default.
• W3044281874 cites W2401455386 @default.
• W3044281874 cites W2462608063 @default.
• W3044281874 cites W2529484692 @default.
• W3044281874 cites W2556232360 @default.
• W3044281874 cites W2593135817 @default.
• W3044281874 cites W2594476307 @default.
• W3044281874 cites W2606362332 @default.
• W3044281874 cites W2610805567 @default.
• W3044281874 cites W2613520543 @default.
• W3044281874 cites W2614700106 @default.
• W3044281874 cites W2747291617 @default.
• W3044281874 cites W2790941732 @default.
• W3044281874 cites W2799372507 @default.
• W3044281874 cites W2889082134 @default.
• W3044281874 cites W2889646458 @default.
• W3044281874 cites W2903493423 @default.
• W3044281874 cites W2905261044 @default.
• W3044281874 cites W2911909558 @default.
• W3044281874 cites W2920969903 @default.
• W3044281874 cites W2925660815 @default.
• W3044281874 cites W2949746977 @default.
• W3044281874 cites W2973690129 @default.
• W3044281874 cites W2986633517 @default.
• W3044281874 cites W2993636547 @default.
• W3044281874 cites W2999689606 @default.
• W3044281874 cites W3035371872 @default.
• W3044281874 doi "https://doi.org/10.7150/thno.48392" @default.
• W3044281874 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7415814" @default.
• W3044281874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32802199" @default.
• W3044281874 hasPublicationYear "2020" @default.
• W3044281874 type Work @default.
• W3044281874 sameAs 3044281874 @default.
• W3044281874 citedByCount "16" @default.
• W3044281874 countsByYear W30442818742021 @default.
• W3044281874 countsByYear W30442818742022 @default.
• W3044281874 countsByYear W30442818742023 @default.
• W3044281874 crossrefType "journal-article" @default.
• W3044281874 hasAuthorship W3044281874A5001611482 @default.
• W3044281874 hasAuthorship W3044281874A5010549062 @default.
• W3044281874 hasAuthorship W3044281874A5045042817 @default.
• W3044281874 hasAuthorship W3044281874A5045238287 @default.
• W3044281874 hasAuthorship W3044281874A5047091127 @default.
• W3044281874 hasAuthorship W3044281874A5059169023 @default.
• W3044281874 hasAuthorship W3044281874A5062987908 @default.
• W3044281874 hasAuthorship W3044281874A5080877411 @default.
• W3044281874 hasAuthorship W3044281874A5081477925 @default.
• W3044281874 hasAuthorship W3044281874A5089050618 @default.
• W3044281874 hasAuthorship W3044281874A5090066209 @default.

• next